23.12.2010 • NewsAbbottblood glucose testing stripsrecall

Blood Glucose Testing Strips Recalled by Abbott

Abbott Laboratories is recalling as many as 359 million blood glucose testing strips that could give false results to diabetics, the company and U.S. regulators said on Wednesday.

Abbott said the strips - used with its Precision Xtra, Precision Xceed Pro, MediSense Optium, Optium, OptiumEZ and ReliOn Ultima glucose monitoring systems - should not be used and would be replaced at no cost.

The company said it uncovered the problem after a routine internal review found that certain lots of the strips took too long to absorb the blood from a patient's finger, which could lead to falsely low readings of their blood sugar levels.

That could cause patients to try to boost their blood sugar unnecessarily, it said in a statement.

The U.S. Food and Drug Administration, in a separate statement, said it was working with Abbott on the recall.

Affected strips were made between January and May and sold both to consumers and healthcare facilities, the FDA said, adding that exposure of the strips to heat or prolonged storage could also be an issue.

Abbott added that the monitoring systems themselves are not affected by the recall.

Innovation Pitch

The Start-up Platform for Chemistry & Life Sciences
Discover Tomorrow’s Innovators

The Start-up Platform for Chemistry & Life Sciences

CHEManager Innovation Pitch supports innovation in the chemistry and life sciences start-up scene. The platform allows founders, young entrepreneurs, and start-ups to present their companies to the industry.

Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.

most read

Photo
08.11.2024 • News

Future Prospects in Green Chemistry

The Discourse on Green Chemistry Interactive Pitch Competition, held on November 5, 2024, at Wiley's Berlin office as part of Berlin Science Week, showcased a range of innovative projects aimed at addressing critical environmental challenges.

Photo
27.03.2025 • News

J&J to Invest $55 Billion in US Operations

US healthcare giant Johnson & Johnson (J&J) has unveiled plans to invest over $55 billion in the US over the next four years. This significant investment marks a 25% increase compared to the previous four years, the company said.